OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer received an award of 140K CORT derivative securities | OQRO

Home
Insider trades
Corcept Therapeutics
Officer received an award of 140K CORT derivative securities

Insider trades

Insider trade

Officer received an award of 140K CORT derivative securities

Traded Feb 27, 2026 · Filed Mar 4, 2026

CORCorcept TherapeuticsCORT

140K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 27, 2026
Reporting period: Not applicable
Filed with the SEC: Mar 4, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001193125-26-089010
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Mar 4, 2026, 4:13 AM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CORCEPT THERAPEUTICS INC

Issuer CIK

1088856

Ticker

CORT

Reporting person

Gary Charles Robb

Relationship

Officer

Officer title

Chief Business Officer

Security

Stock Option (right to buy)

Table

Derivative (Table II)

Transaction date

Feb 27, 2026

Transaction code

Shares / units

140,000

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

140,000

Ownership form

Direct

Amendment

Footnotes from the filing

Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Around the same time

Joseph K Belanoff (Chief Executive Officer) sold ~$1.31M of Corcept Therapeutics

Scheduled in advanceFiled 6mo ago

James N WilsonDirector

Filed 7mo ago

4,000Shares

Traded Mar 20 · filed 5 days later

Gift or transfer — classified separately from trades.

More Official record

William GuyerChief Development Officer

Filed 7mo ago

12KShares · @ $21.65

Traded Mar 20 · filed 5 days later

Derivative exercise or conversion — not an open-market buy.

More Official record